chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I drove 100 miles in a blinding snowstorm to get my 67 yr old cancer patient husband and an 86yr old  hypertensive freind. There were a majority of vaccines to small towns around the state instead of to the densest most Covid ridden population in the state.  So many cancellations from the many travelling that they closed early and had many openings so I received the COVID shot myself as well.   The two men felt fine after.  My arm hurt badly for the first 3 days, still tender yet much better today, 2/19.  Evening of shot I vomited.  FEb 16,  day extremely tired and  felt overheated all day with muscle aches. .  Vomited in afternoon and evening.  Wed, 17th, ran a fever, slept late and felt dizzy and tired, all day vomiting  every time after trying to eat.  Thur 18th, Vomiting all day with chills and fever.  Unable to get out of bed for more than an hour.  That evening  drank Broth, took 2 Aleve, and didn't vomit. Fever went away.   Had Drenching night sweats requiring change of pajamas twice. Feb 19, very tired sleeping alot. No longer vomiting.  No chills or fever.  Remain  tired and  moderately dizzy.  Not taking anything for this beyond the 2 Aleve the day prior.
Patient had diffuse swelling of right knee and thigh 24 hrs after vaccine - PENTACEL/Hep A.
1/08 12pm- Diarrhea 11pm- Nausea throughout the night 1/09 6am- Vertigo
She passed out.; This is a spontaneous report from a contactable consumer (parent). A 17-year-old female patient (daughter) received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number= EL1284) on 22Jan2021 11:45 AM at left arm at single dose for COVID-19 immunisation. Medical history and concomitant medications were none. No known allergies. Patient was not pregnant. Patient did not have COVID prior vaccination, and did not have other vaccine in four weeks, did not other medications in two weeks. The patient experienced passed out on 22Jan2021 12:00 PM. Treatment included they had her lay on the ground with her knees up and cold compresses. Patient did not test COVID post vaccination. The outcome of event was recovering.
Migraine headache; back ache; Chills; This spontaneous case was reported by a consumer and describes the occurrence of MIGRAINE (Migraine headache), BACK PAIN (back ache) and CHILLS (Chills) in a 76-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 17-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Feb-2021, the patient experienced MIGRAINE (Migraine headache), BACK PAIN (back ache) and CHILLS (Chills). At the time of the report, MIGRAINE (Migraine headache) and BACK PAIN (back ache) outcome was unknown and CHILLS (Chills) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       The treatment information included Ibuprofen.   Most recent FOLLOW-UP information incorporated above includes: On 06-May-2021: Significant follow up added. New events were mentioned.
12x9 C erythema from Dtap 9x9 induration around injection site given 4 days ago.
Information has been received from a nurse concerning an unknown number of patients who were vaccinated with Gardasil.  Subsequently some of the patients who received the vaccine in the recommended areas such as the deltoid and the thigh, experienced pain, swelling and redness at the injection site.  However, an unknown number of patients also may have received the vaccine IM in the buttocks without experiencing any side effects.  No further details were provided.  Follow up information from a healthcare professional indicated that there were 2 patients who experienced pain, swelling and redness, and no further identifying patient details were available.  Additional information has been requested.
Contracted covid about 3 weeks after taking the vaccine. Was given an anti viral paxlovid. Was feeling better after 3 days
PATIENT CAME IN ON 10.06.19 TO EXPLAIN ABOUT THE REACTIONS FROM PNEUMOVAX VACCINE SHE RECEIVED ON 10.02.19.  SHE HAS SWELLING ON THE AREA AROUND INJECTION SITE (3X6-7 INCH) THAT WAS RED AND WARM. SHE HAS BEEN EXPERIENCING FEVER, PAIN,HEADACHE, AND HARDSHIP MOVING HER LEFT ARM SINCE APPROXIMATELY 1 DAY AFTER THE INJECTION. I RECOMMENDED HER TO GO TO THE DOCTOR AND SHE WENT TO THE URGENT CARE.   I RECEIVED PRESCRIPTION FOR ANTIBIOTIC(KEFLEX) AND FILLED FOR HER.
First night fever/chills, body ache headache. Next day persistent migraine, then trigeminal neuralgia episode until day 4. Arm sore on first day, then golfball knot and hot red rash spread around site---hurts. Rash (small hives) on right side of face, under chin, and neck on right side very itchy and hot.
This spontaneous report as received from a pharmacist via a consumer refers to a lot of patients of unknown age. The consumer reported "a lot of her friends" developed shingles on an unknown date after receiving ZOSTAVAX (lot #, expiration date, dose, route and indication not reported) on an unknown date. The outcome of the events was unknown. This is one of several reports received from the same source. Additional information is not expected.
Breakthrough case admission after 2 vaccines Moderna 4/10/21 lot# 008B21-2A; Moderna 5/8/21 lot# 043B21A
This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a female patient of unknown age.  No information was provided regarding concurrent conditions, medical history, or concomitant medications. On or about 12-MAR-2018, a pharmacist at a pharmacy administered ZOSTAVAX to the patient to obtain permanent prevention and protection against shingles and zoster-related injuries/conditions (dose, route, and lot # not provided). On or about 14-APR-2018, the patient was treated by a physician at a walk-in facility for shingles. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with ZOSTAVAX, and suffered serious physical, emotional, and economic damages as a result of the patient's injuries. As a direct and proximate result of ZOSTAVAX, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs including care for hospitalization, physician care, monitoring, treatment, medications and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; lost wages; loss of earnings capacity; and other losses and damages. The outcome of the events was not recovered. Causality assessment was related. Additional information has been requested.
This spontaneous report was received from a doctor of pharmacy refers to a patient of unknown age (gender unspecified). On 04-DEC-2012, the patient was vaccinated with an expired dose of ZOSTAVAX, lot number reported as (671452/1124AA, expiry date: 12-OCT-2012, dose and route not reported). No concomitant medications were reported. No symptoms were reported. This is one of the two reports received from the same reporter. Additional information has been requested.
Inappropriate schedule of product administration; A spontaneous report was received from a HCP concerning a 31-year-old female patient , who received Moderna's COVID-19 vaccine (mRNA-1273) and administered second dose of Moderna vaccine to a patient 22 days after first dose.  The patient's medical history was not provided. Concomitant medication as provided by the reporter was unknown.  On 23 Mar 2021, prior to the onset of the event, the patient received their second of two planned doses of mRNA-1273 (Lot number: 045A21A) through intramuscular route in left arm for prophylaxis of COVID-19 infection and administered second dose 22 days after first dose  No treatment information was provided.  Action taken with mRNA-1273 in response to the event was not applicable.  The outcome of the event inappropriate schedule of vaccine administration was considered resolved.; Sender's Comments: This report refers to a case of inappropriate schedule of vaccine administered for mRNA-1273, lot # 045A21A  with no associated AEs.
0900 Pt. c/o feeling warm, dizzy and lightheaded. Remained conscious. Head lowered below legs initially. 0902 assisted to lying down  , c/o nausea, states feeling tired and weak. BP 140/90, P 100R 24. Lungs clear to auscultation. Sips of H20 taken. 0908 BP 128/86, P80 RR 16. 0915  BP 120/88 Nausea and dizziness relieved per pt. Assisted to sit in chair. Denies Hx of HTN. Advised to see Dr. re: BP. 0927 BP 120/90. P88 R18. pt. assisted walking to be driven home by her S/O in waiting car. Pt. advised to call emergency if any serious symptoms occur. Pt. states she understands.
Information has been received from a physician concerning a female between 12 and 15 years of age with a history of obesity who was vaccinated SC with a second dose of VARIVAX (Oka/Merck). Concomitant therapy included PEDIARIX and MENACTRA. In approximately February 2008, the patient experienced severe swelling at the injection site and developed a rash that ran down their arm. The patient was diagnosed with cellulitis and was treated with antibiotics. The patient was hospitalized. The outcome was reported as recovered. There was no product quality complaint. Additional information has been requested.
This spontaneous report as received from a Certified Medical Assistant refers to a patient of unknown age and gender. On 19-FEB-2013 the patient was vaccinated with first dose of GARDASIL (dose, route, lot # not reported). On 21-FEB-2014 the patient received second dose and on 24-APR-2014 received a third dos of GARDASIL (dose, route, lot # not reported). On unknown date the patient was vaccinated with inappropriate schedule of GARDASIL. Moreover on 11-SEP-2014 (reported as "now") the patient was in the doctor's office to possibly receive a fourth dose of GARDASIL. Additional information has been requested.
orange pee after the vaccine; This spontaneous case was reported by a consumer and describes the occurrence of CHROMATURIA (orange pee after the vaccine) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced CHROMATURIA (orange pee after the vaccine). At the time of the report, CHROMATURIA (orange pee after the vaccine) outcome was unknown.            No concomitant medications were provided by the reporter. No treatment information was provided by the reporter.
Vaccinated at 2:10 pm April 9th. Began feeling chills and body aches around 8pm same day. Had 101 degree fever at around midnight. Stood up to get water and fainted at approximately 2am April 10th. Was treated at hospital emergency room around 2:30 am. Was given 1 round of IV fluids and 1000mg Tylenol. Was discharged at about 8am April 10th.
Information has been received from a pharmacist reported that a 25 year old female with no allergies received PNEUMOVAX (Lot# 662742/1117X), unknown dose, once, intravenously instead of intramuscularly (IM), a few minutes ago, on 31-JAN-2009 for vaccination. The patient's relevant medical history includes that she was post surgery; admission date was 31-JAN-2009. She had PERCOCET, so it was in her system and also had the influenza virus vaccine (manufacturer unknown) today 31-JAN-2009 before the PNEUMOVAX vaccine. The patient's relevant concomitant medications included COLACE, DILAUDID, CHROMAGEN CAPSULES, PHENERGAN, and TORADOL. The patient's relevant past drug history was unknown. On 31-JAN-2009, a nurse administered the PNEUMOVAX a few minutes ago IV instead of IM. The physician had been notified. It was unknown if any laboratory testing had been performed. As of 31-JAN-2009, it was unknown if the patient continued to take PNEUMOVAX vaccine and the pharmacist stated that she assumed that the patient was okay right now because she had not heard anything or gotten any orders for any medications and that the physician was monitoring the patient and was considering the Epipen. Follow-up information was received from the physician concerning the 24 year old female with no illness at time of vaccination, pre-existing allergies, birth defects or medical conditions. It was reported that there was no adverse event. The patient was observed in hospital for 12-24 hours after the event which prolonged hospitalization. No relevant diagnostic tests were performed. No further information is available.
Patient complains of "dead arm"/pain in shoulder radiating down arm.  Vaccine may have been given too high in the arm (joint space)
Immunizations DTaP, IPV, HIB, Hep, Pneumococcal given 09/25/02. On 09/26/02, parents brought children very cranky, Temperature 100.6 rectally, ?Viral vs reaction, No redness, no swelling noted #@ injection sites on legs, 09/27/02 spoke with dad on phone, Eating and acting fine now, No further concerns.
onset of sx was about 5-7min p/vax;mild ringing in ears lasting about 2 or 3minutes;no tx necessary;
Information has been received from a literature article, referring to a 26-year-old male patient with common variable immunodeficiency (CVID) with an intrinsic microdeletion of chromosome 1q42.1-42.3, where gene for inositol 1,3,4, trisphosphate kinase beta (ITPKB) was localized. ITPKB had an important role in the development, survival and function of B cells. In this subject, the expression of ITPKB mRNA as well as ITKPB protein was significantly reduced. The sequencing of ITPKB gene revealed three variants, two of them were missense variants and third was a synonymous variant. On an unknown date, the patient was vaccinated with PNEUMOVAX 23 (lot#, dose, dose# and route unknown) for prophylaxis. On an unknown date, the patient did not respond to any of the 14 serotypes of Streptococcus pneumoniae following PNEUMOVAX 23 vaccination (therapy non-responder). Streptococcus pneumonia antibodies (14 serotypes) were 0.00.3 microgram/ml (reference range: more than 1.3 microgram/ml). The patient showed markedly impaired response to T-independent pneumococcal polysaccharide antigens. The outcome of therapy non-responder was unknown. The author considered therapy non-responder to be related to PNEUMOVAX 23.
Local rash and soreness around sight of vaccine. Lasted 5 days. Rash was red and splotchy.
L deltoid area with redness, warmth approximately 6cm X 4cm. No induration temperature 99.4 f (tympanic) Rx: Apply cold compresses to site pm Tylenol pm.
no additional AEs; patients received doses of VARIVAX vaccine on 8/9/22 while improperly stored outside recommended storage temperature range; This spontaneous report has been received from a registered nurse regarding a 16 years-old patient of unknown gender. The patient's concomitant medications, pertinent medical history, and drug reactions/ allergies were not reported.  On 03-AUG-2022, varicella virus vaccine live (oka/merck) (VARIVAX) was exposed to -14 Fahrenheit (F) up to 46 F (14F) for 4 hours (h) 15 minutes (min). On 09-AUG-2022, the vaccine was exposed to 14 F up to 46 F (45F) for 4 h 45 min. On the same day, the patient was vaccinated with one dose of a stored outside the recommended storage temperature range of varicella virus vaccine live (oka/merck) (VARIVAX) subcutaneous injection, subcutaneously, on the right deltoid at a dose of 0.5 milliliters (ml), once (lot number: W002596, which was verified to be valid, with an expiration date: 24-JAN-2024; strength was not reported) (product storage error). The reporter called for an evaluation of vaccine temperature stability. There was no additional adverse event (AE) reported, and no further information was provided.  This is one of several reports from the same reporter.
15DEC 30 mins p/vax states sx were seeing spots, severe h/a, fever (felt warm) BP taken by nurse 190/120; upper resp sx dx bronchitis;
Information has been received from a physician concerning a female who on 27-OCT-2008 was vaccinated with (lot #660685/0619X). In October 2008, the patient experienced spiking fever and a big arm and was admitted to the hospital. The patient's spiking fevers and a big arm persisted. The physician stated he was given a "bad batch" of PNEUMOVAX. A lot check has been requested. This is one of several reports from the same physician. A standard lot check investigation was performed. All in-process quality checks for the lot number in question were satisfactory. The lot met the requirements of the Agency and was released.
This spontaneous report as received from a pharmacist refers to a female patient of unknown age. On an unknown date the patient was vaccinated with ZOSTAVAX (dose, indication, route and lot were not reported) froma different pharmacy. On an unknown date, the patient expereienced rash on her arm. The outcome of rash on her arm was unknown. Additional information has been requested.
Diarrhea started on July 29, 2023.  Also had slight muscle aches prior.  Diarrhea lasted 3 days, but I'm still not feeling back to normal.  Have just been taking  tylenol and eating very light bland foods.
On 1/3/00, immediately following the vax, the pt developed a fever of 100, a swollen arm was confined to the arm. At the time of the report, the pt's swollen arm and fever had persisted. Additional information has been requested.
Raised rash; red rash at injection site; tired; This spontaneous case was reported by a consumer and describes the occurrence of RASH PAPULAR (Raised rash), VACCINATION SITE ERYTHEMA (red rash at injection site) and FATIGUE (tired) in a 47-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 088D21A) for COVID-19 vaccination.     No Medical History information was reported.    On 11-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Aug-2021, the patient experienced FATIGUE (tired). On 19-Aug-2021, the patient experienced RASH PAPULAR (Raised rash) and VACCINATION SITE ERYTHEMA (red rash at injection site). On 11-Aug-2021, FATIGUE (tired) had resolved. At the time of the report, RASH PAPULAR (Raised rash) and VACCINATION SITE ERYTHEMA (red rash at injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.     No treatment medications were provided by reporter. No concomitant medications were provided by reporter.
Patient described numbness and pain throughout Left Arm within 15 minutes after vaccination; she stated this happened with her 1st shot as well but that did not occur until 12-18 hours after the shot.  No redness, no swelling observed at injection site by myself.  I gave the patient and ice pack to help with the pain/discomfort.
Caller takes pain relievers/nsaid and wants to know the efficacy of that combination; Caller takes pain relievers/nsaid and wants to know the efficacy of that combination; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team for a Pfizer sponsored program (159558). The reporter is the patient.  A female patient received bnt162b2 (BNT162B2), administration date 23Apr2021 (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: PRODUCT USE ISSUE (non-serious), PAIN (non-serious), outcome "unknown" and all described as "Caller takes pain relievers/nsaid and wants to know the efficacy of that combination".  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
11/22/22 presents to EC ED for "fatigue". PMHx of "HTN, CAD, DM2, afib on warfarin, CVA"
vaccinated on 10/7/2021 tingling in itchy face 2 hours post vaccination. face tightness. By 5:30 pm noticeable swelling to cheeks face and sinuses . Informed by PCP to take Benadryl on 10/8/2021 swelling decreased but still present
Pain, redness, swelling, heat, hardness around inj site.  Temp 99.8.  Pt. drinking fluids well & active.  Tylenol administered.
RANDOM CHEST PAIN AND SHORTNESS OF BREATH SINCE FEW DAYS AFTER THE SECOND DOSE OF VACCINE.
Rt arm redness 1/2" diameter some swelling and just noted. Client was seen in ER at hospital by Dr. Benadryl steroids and Bactrim per mom.
PATIENT RECEIVED VACCINE FROM OUTSIDE SOURCE PERIPHERAL NEUROPATHY 11/9/2022  --  RECURRENCE OF SAME SYMPTOMS
he had his 2nd dose of the vaccine 2 months ago and 7 days after that his lymph nodes were swollen and sore; he had his 2nd dose of the vaccine 2 months ago and 7 days after that his lymph nodes were swollen and sore; the base of his neck is also swollen, not that swollen but it is visible; This is a spontaneous report from a contactable consumer (patient). A 55-years-old male patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Batch/Lot/NDC/UPC number and Expiry date were unknown), via an unspecified route of administration, administered in right arm on an unspecified date as dose 2, single for covid-19 immunization. Medical history included first dose of COVID-19 Vaccine as immunisation. Concomitant medications were not reported.The patient he had his 2nd dose of the vaccine 2 months ago and 7 days after that his lymph nodes were swollen and sore (lymphadenopathy), (lymph node pain), the base of his neck is also swollen, not that swollen but it is visible (swelling). Patient stated he had the second dose of the Pfizer vaccine and 7 days after he got it his lymph nodes were sore and swollen. He added that, he never had a swollen lymph nodes before not until he got the 2nd dose of the Pfizer BioNTech COVID-19 Vaccine. Patient stated, "Yes, mostly it was on the side that I had gotten the shot and it was painful to the touch and lot more than it is now and now I have lymph node (Incomplete sentence)." His right side is now going down to normal but his left lymph nodes are still swollen. Patient said, he already contacted CDC and reported his side effects but according to CDC they don't have information about swollen lymph nodes. He wants to know what to do. He's not capable of seeing an HCP and don't want to spend money for it. He has no insurance and is upset. Caller also stated that we really don't care about them. Caller is upset because of his swollen lymph nodes from 2 months ago for his 2nd dose of the vaccine. About 7 days afterwards his lymph nodes swell and currently now after just being the left side it is in both sides that is swollen after 2 months and he says that it is painful as well." The outcome of the events was unknown.  Information on the lot/batch number has been requested. Complainant hung up abruptly/transfer incomplete.
Generally ill feeling. body aches, chills, cold sweat, headache, slight fever.